Antibody Discovery Benchmark: 100 evals to test AI agents' scientific decisions across drug discovery
kenbwork · x · 2026-09-03
A new Antibody Discovery Benchmark tests whether AI agents can make sound scientific decisions across therapeutic antibody discovery: 100 evaluations across ten areas from real drug programs, including target/modality selection, assay design, binder discovery, binding characterization, cellular pharmacology, antibody engineering, and preclinical de-risking. It emphasizes that antibody discovery is multiparameter and context-dependent—display enrichment can reflect amplification bias rather than binding, and strong binding to purified antigen may not translate to native cell-surface recognition.
Related event: LatchBio Releases Antibody Discovery Benchmark for AI Agents(5 posts)→
More from Research
- TRACE Open-Sourced: Migrating G1 Controller to Full-Size Humanoid H2 in 8 Hours on One GPU — zhengyiluo · 2026-10-18
- Humanoid Robot Funding Tops $3B as Brian Potter Explains the VLA Models Driving Robots — scottleibrand · 2026-10-18
- Terence Tao on 'War Footing' as OpenAI Claims Navier-Stokes Solve Shakes Mathematics — AlexTensor · 2026-10-18
- Univ. of Tokyo paper: why your recorded voice feels eerie — a vocal uncanny valley — ssh4net · 2026-10-18
- MIT's SANDO Drone Planner Avoids Every Moving Obstacle Across 12 Real Flights — Olivier__OG · 2026-10-18
- No-backprop pretraining speedup of 2.3x claimed, inspired by mech interp essay — CatAstro_Piyush · 2026-10-18